Anzeige
Meldung des Tages: 25 % Ölpreisschock am Wochenende – profitiert jetzt dieser Effizienz-Hidden-Champion?

Immunic

Aktie
WKN:  A2PHD4 ISIN:  US4525EP1011 US-Symbol:  IMUX Branche:  Biotechnologie Land:  USA
1,088 €
+0,014 €
+1,30%
11:51:54 Uhr
Depot/Watchlist
Marktkapitalisierung *
47,04 Mio. €
Streubesitz
61,15%
KGV
-0,79
Index-Zuordnung
-

Unternehmensmeldungen

03.03.26 - EQS
EQS-News: Immunic to Participate in Investor Conferences in March
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Investor Conferences in March 03.03.2026 / 12:30 CET/CEST The issuer is solely responsible for the ...
26.02.26 - EQS
EQS-News: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
Issuer: Immunic AG / Key word(s): Annual Results Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update 26.02.2026 / 12:30 CET/CEST The ...
17.02.26 - EQS
EQS-News: Immunic Announces Closing of Oversubscribed Private Placement Financing
Issuer: Immunic AG / Key word(s): Financing Immunic Announces Closing of Oversubscribed Private Placement Financing 17.02.2026 / 22:05 CET/CEST The issuer is solely ...
13.02.26 - EQS
EQS-News: Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
Issuer: Immunic AG / Key word(s): Financing Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-​Stage ...
04.02.26 - EQS
EQS-News: Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Issuer: Immunic AG / Key word(s): Conference/Study results Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, ...
07.01.26 - EQS
EQS-News: Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Issuer: Immunic AG / Key word(s): Miscellaneous/Conference Immunic Highlights 2025 Accomplishments and Upcoming Milestones 07.01.2026 / 12:30 CET/CEST The issuer is ...
26.11.25 - EQS
EQS-News: Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December 26.11.2025 / 12:30 CET/CEST The issuer ...
13.11.25 - EQS
EQS-News: Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Issuer: Immunic AG / Key word(s): 9 Month figures Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update 13.11.2025 / 12:30 CET/CEST The ...
29.10.25 - EQS
EQS-News: Immunic to Participate in Industry and Investor Conferences in November
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Industry and Investor Conferences in November 29.10.2025 / 11:30 CET/CEST The issuer is solely ...
01.10.25 - EQS
EQS-News: Immunic to Participate in Scientific and Investor Conferences in October
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in October 01.10.2025 / 12:30 CET/CEST The issuer is solely ...
25.09.25 - EQS
EQS-News: Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
Issuer: Immunic AG / Key word(s): Conference/Study results Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in ...
09.09.25 - EQS
EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
Issuer: Immunic AG / Key word(s): Patent Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple ...
04.09.25 - EQS
EQS-News: Immunic to Participate in Investor and Scientific Conferences in September
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in September 04.09.2025 / 12:30 CET/CEST The issuer is solely ...
07.08.25 - EQS
EQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Issuer: Immunic AG / Key word(s): Quarter Results Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update 07.08.2025 / 12:30 CET/CEST ...
24.06.25 - EQS
EQS-News: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Issuer: Immunic AG / Key word(s): Study/Study results Immunic Reports New, Positive Long-Term Open-​Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus ...
05.06.25 - EQS
EQS-News: Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
Issuer: Immunic AG / Key word(s): Study/Study results Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional ...
02.06.25 - EQS
EQS-News: Immunic to Participate in Investor, Scientific and Industry Conferences in June
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Investor, Scientific and Industry Conferences in June 02.06.2025 / 12:30 CET/CEST The issuer is solely ...
02.05.25 - EQS
EQS-News: Immunic to Participate in Scientific and Industry Conferences in May
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Scientific and Industry Conferences in May 02.05.2025 / 12:30 CET/CEST The issuer is solely responsible ...
30.04.25 - EQS
EQS-News: Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Issuer: Immunic AG / Key word(s): Study results Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis ...
10.04.25 - EQS
EQS-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Issuer: Immunic AG / Key word(s): Financing Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments 10.04.2025 / 19:00 ...

Newssuche

Videos

newspaper
04.03.26 +11,04%
ROHÖL mit Ziel MINUS 40$?!?
Fundierte Strategien für den Handel der wichtigen News in einem Seminarpaket, plus transparenter ... Mehr »